Investor News
US Government Agreement with Former CEO
Read moreAppointment of Chief Executive Officer
Read moreNew Data from the RECOVER™ Study Reveal Two-Year Outcomes in People with Opioid Use Disorder Following Transition from Pivotal Phase 3 Clinical Trials to a Real-World Setting
Read moreIndivior Announces Patent Trial and Appeal Board Ruling in Dr. Reddy’s Laboratories (DRL)’s Petition for Inter Partes Review of U.S. Patent No. 9,687,454 (the ‘454 Patent)
Read moreQ1 2020 Indivior Financial Results Press Release
Read moreIndivior receives approval for SUBUTEX® prolonged release solution for injection, 100mg and 300mg for substitution treatment of opioid dependence in Sweden
Read moreIndivior Q1 2020 Financial Results
| Thursday May 14, 2020 | The information provided below is provisional and subject to…
Read more